Abstract:Heart failure (HF) as a result of myocardial infarction (MI) is a major cause of fatality worldwide. However, the cause of cardiac dysfunction succeeding MI has not been elucidated at a sarcomeric level. Thus, studying the alterations within the sarcomere is necessary to gain insights on the fundamental mechansims leading to HF and potentially uncover appropriate therapeutic targets. Since existing research portrays regulatory light chains (RLC) to be mediators of cardiac muscle contraction in both human and animal models, its role was further explored In this study, a detailed characterisation of the physiological changes (i.e., isometric force, calcium sensitivity and sarcomeric protein phosphorylation) was assessed in an MI mouse model, between 2D (2 days) and 28D post-MI, and the changes were related to the phosphorylation status of RLCs. MI mouse models were created via complete ligation of left anterior descending (LAD) coronary artery. Left ventricular (LV) papillary muscles were isolated and permeabilised for isometric force and Ca2+ sensitivity measurement, while the LV myocardium was used to assay sarcomeric proteins' (RLC, troponin I (TnI) and myosin binding protein-C (MyBP-C)) phosphorylation levels and enzyme (myosin light chain kinase (MLCK), zipper interacting protein kinase (ZIPK) and myosin phosphatase target subunit 2 (MYPT2)) expression levels. Finally, the potential for improving the contractility of diseased cardiac papillary fibres via the enhancement of RLC phosphorylation levels was investigated by employing RLC exchange methods, in vitro. RLC phosphorylation and isometric force potentiation were enhanced in the compensatory phase and decreased in the decompensatory phase of HF failure progression, respectively. There was no significant time-lag between the changes in RLC phosphorylation and isometric force during HF progression, suggesting that changes in RLC phosphorylation immediately affect force generation. Additionally, the in vitro increase in RLC phosphorylation levels in 14D post-MI muscle segments (decompensatory stage) enhanced its force of isometric contraction, substantiating its potential in HF treatment. Longitudinal observation unveils potential mechanisms involving MyBP-C and key enzymes regulating RLC phosphorylation, such as MLCK and MYPT2 (subunit of MLCP), during HF progression. This study primarily demonstrates that RLC phosphorylation is a key sarcomeric protein modification modulating cardiac function. This substantiates the possibility of using RLCs and their associated enzymes to treat HF.

Covalent crosslinking of neurofilaments in the pathogenesis of n-hexane neuropathy.

Hemodynamic regulation: investigation by spectral analysis.

Actin-binding compounds that affect the kinetics of the interaction of cardiac myosin with actin

Mechanistic analysis of actin-binding compounds that affect the kinetics of cardiac myosin-actin interaction

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases

Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators

Danicamtiv reduces myosin's working stroke but enhances contraction by activating the thin filament

Fast skeletal myosin binding protein-C expression exacerbates dysfunction in heart failure

Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor

[Reverse root canal filling using glass cement. First experiences].

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Small molecule-mediated refolding and activation of myosin motor function

Functional and Molecular Characterisation of Heart Failure Progression in Mice and the Role of Myosin Regulatory Light Chains in the Recovery of Cardiac Muscle Function

Phosphorylation of cardiac myosin–binding protein-C contributes to calcium homeostasis

Actin-Myosin Interaction: Structure, Function and Drug Discovery

Neutraceuticals silybin B, resveratrol and epigallocatechin-3 gallate (EGCG) bind to troponin to restore the loss of lusitropy caused by cardiomyopathy mutations in vitro, in vivo, and in silico

Giant-cell reparative granuloma-like lesion in the femoral heads of rats during the early repair phase of osteonecrosis

Carvedilol Activates a Myofilament Signaling Circuitry to Restore Cardiac Contractility in Heart Failure

Abstract P1118: Genetic Validation Of Cardiac Cytoskeleton And Extracellular Matrix Targets For Drug Discovery

On the Capacity of Tandem Server, Finite Queue, Service Systems